Albert Robichaud - 13 Feb 2023 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Reporting relationship: Chief Scientific Officer
Issuer ticker: SAGE
Reported as of: 13 Feb 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 15 Feb 2023, 15:47:01 UTC
Prior SEC filing: 07 Feb 2023
Source filing: View source filing
Reporting owner signature: /s/ Jennifer Fitzpatrick, as Attorney-in-Fact for Albert Robichaud

Key filing fact

Albert Robichaud filed Form 4 for Sage Therapeutics, Inc. (SAGE) on 15 Feb 2023.

Key facts

This page summarizes Albert Robichaud's Form 4 filing for Sage Therapeutics, Inc. (SAGE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 15 Feb 2023, 15:47.

Change

Previous filing in this sequence was filed on 07 Feb 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SAGE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +16,720
Change %
Price: $0.000000
Shares after: 16,720
Date: 13 Feb 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 16,720
Exercise price: $45.28
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The securities awarded on February 13, 2023 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. Options to purchase 4,180 shares of common stock shall vest on the one year anniversary of February 13, 2023, with 12,540 shares vesting in 36 equal monthly installments thereafter.